Transcript
Transcript

COVID-19 Epidemiology Projections, Therapeutics & Vaccine Implementation – 31 July 2020

  • Multi Asset
  • Healthcare
  • North America

Specialist

Associate Professor at Fred Hutchinson Cancer Research Center (Fred Hutch)

Agenda

  • COVID-19 characteristics and epidemiology
  • Vaccine trial design for phases 2-3 and clinical results from COVID-19 vaccines, including Moderna's (NASDAQ: MRNA) mRNA-1273 and AstraZeneca's (LON: AZN) AZD1222
  • COVID-19 vaccine implementation scenarios – different efficacy profiles, side effects, disease severities and population characteristics
  • Outpatient treatment for early stages of COVID-19 – use of convalescent plasma, hydroxychloroquine, dexamethasone, favipiravir, lopinavir-ritonavir and emtricitabine-tenofovir
  • Peaks and troughs of viral loads in COVID-19 patients and implications on diagnostic testing

Questions

Access the full Transcript

Submit your details to read this transcript in full.

The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited